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Background: Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with
non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are
lacking.
Methods: Previously untreated patients with non-resectable mCRC were to receive capecitabine (1,250 mg/sqm bid
d1-14 oral) and bevacizumab (7.5 mg/kg i.v.) every 3 weeks. Progression-free survival (PFS) was the primary
endpoint. Secondary endpoints include overall survival (OS), objective response rate (ORR) and toxicity.
Results: 82 pts were included: 40 female, median age 70 (range 50–86). ECOG PS 0/1/2 was 38/52/10%,
respectively. Synchronous metastases were present in 58 pts. 16 pts had primary tumor in situ. Median treatment
duration was 4.1 months (6 cycles). Toxicity was generally mild. ORR was 38%, with 5 complete and 23 partial
responses. Median PFS was 7.0 months [95% CI (5.0-9.1)] and OS 17.9 months [95% CI (14.6-21.6)]. Second- and
third-line systemic therapy was given to 57% and 33% of pts, respectively.
Conclusions: Besides the favourable tolerability, PFS and OS were shorter than reported by other trials. Careful
patient selection for upfront capecitabine and bevacizumab is essential.
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Colorectal cancer (CRC) is the most frequently diag-
nosed cancer in Europe and one of the leading causes of
cancer death worldwide [1,2]. Several first-line treatment
options for metastatic CRC (mCRC) are currently available,
incorporating fluoropyrimidines, irinotecan, oxaliplatin,
bevacizumab and epidermal growth factor receptor (EGFR)
antibodies (i.e. cetuximab and panitumumab) for (K)RAS
wildtype patients [3-8].
Current guidelines recommend first line single agent
fluoropyrimidine with or without bevacizumab for patients
without an option for resection, either due to location or
comorbidity, and asymptomatic/low volume disease (so* Correspondence: arnold@tumorbio.uni-freiburg.de
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reproduction in any medium, provided the orcalled group 3 patients) [9]. The combination of 5-
fluorouracil and bevacizumab was established by two
randomized phase II trials, demonstrating prolonged
progression free (PFS) and overall survival (OS) and
higher objective response rates (ORR) for the addition
of bevacizumab to a bolus regimen of 5-fluorouracil
and leucovorin (5FU/LV) [10,11]. These trials included
either unselected patients or patients considered to be
not optimal candidates for first line irinotecan. At the time
of initiation of the current study no prospectively collected
data of the combination of the oral fluoropyrimidine
capecitabine and bevacizumab were available.
Later the Australasian Gastrointestinal Trials Group
(AGITG) MAX trial evaluated capecitabine +/−
bevacizumab, with a third arm adding mitomycin, in
patients suitable for capecitabine single agent. The
combination of capecitabine and bevacizumab showed
significantly prolonged PFS (8.5 vs. 5.7 months,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for OS and ORR [12].
Moreover, several single arm phase II trials and a ran-
domized phase III trial were applying capecitabine and
bevacizumab in elderly patients (≥70 years of age)
[13-16]. In this particular patient group capecitabine
and bevacizumab was feasible and efficacious with a re-
sponse rate of about 20% and a median PFS of 9.1-
11.5 months. Despite the recommendation, data on the
use of capecitabine and bevacizumab in definitely non-
resectable patients independent of appropriateness for
intensive first line treatment are scarce.Methods
Patient selection
Patients were required to have a histological confirmed
diagnosis of mCRC not amenable for upfront or secondary
resection (defined as no option for curative treatment
either initially or after reduction in size of metastases after
chemotherapy), Eastern Cooperative Oncology Group per-
formance status of 0–2, measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0 and adequate hematological, renal, and hepatic
function defined by the following criteria: neutrophil
count ≥1500/mm3, platelet count ≥ 100 000/mm3,
creatinine-clearance ≥ 30 ml/min, total serum bilirubin ≤ 2
times the upper limit of the institutional normal range
(ULN), and transaminases ≤ 2,5 times ULN. Exclusion cri-
teria included prior chemotherapy for metastatic disease
(adjuvant chemotherapy completed at least 6 months
before trial inclusion was allowed); other active malignancy
within the preceding year except for adequately treated
basal cell cancer, or in situ cervical cancer; clinical evidence
of central nervous system - metastases; major operation or
injury within 28 days; and clinically significant cardiovascu-
lar disease.
All patients provided written informed consent before
study entry according to institutional regulations. The
trial was approved by the institutional review board and
the competent authority (Paul Ehrlich Institut) and reg-
istered (EudraCT number: 2005-001919-21).Treatment administration
All patients received capecitabine and bevacizumab in
a 3-weekly cycle. Capecitabine was administered with
1250 mg/m2 body surface area orally twice-daily days
1–14. The daily dose of capecitabine was calculated to
the next 500 mg dose level. If the calculated dose was
< 400 mg above the last 500 mg dose level, it was
rounded down. If it was ≥ 400 mg above it, it was rounded
up to the next 500 mg dose level. Bevacizumab was
administered with 7.5 mg/kg body weight as an intravenous
infusion on day 1.Dose adjustments
New treatment cycle was scheduled if neutrophil count
was ≥ 1500/mm3, platelet count was ≥ 100 000/mm3,
and all relevant non-hematological toxic effects were grade
1 or lower (NCI CTC AE v 3.0). Dose reductions were
based on the toxicity in the preceding cycle. Capecitabine
doses were reduced by 25% for any grade 3 or 4
hematological toxicity, except anemia. Treatment was
held for grade 3 non-hematological adverse events
(excluding alopecia, nausea or vomiting), until reso-
lution to grade 1 or lower, and resumed at a 25% reduc-
tion and discontinued for grade 4 non-hematological
adverse. In case of a drug specific adverse event, e.g.
hand-foot syndrome for capecitabine the suspected drug
was reduced. Capecitabine was reduced by 25% for
mild renal impairment with creatinine clearance from
30 to 50 ml/min. Patients requiring a treatment delay
of more than 2 weeks due to toxicity or more than two
dose reductions were removed from the study. In
addition, patients were removed from study for disease
progression, unacceptable toxicity, or withdrawal of
consent.
Study evaluations
Pretreatment evaluation included a complete medical his-
tory, physical examination, routine hematology, biochem-
istry and urine analyses, and computed tomography (CT)
scans of the abdomen and pelvis and thoracic CT scan in
case of pulmonary metastases. Hematological (including
platelet and differential) analyses, serum chemistry, and
urine dipstick were obtained at day 1 in each cycle. Sub-
jective symptoms, physical examination results, vital signs
(including blood pressure), performance status, and all ad-
verse reactions were recorded before each treatment cycle
according to NCI CTC AE v 3.0. CT scans were
performed every 9 weeks (three cycles) to assess disease
status. Response rate was evaluated according to RECIST
1.0 [17].
Statistical considerations
The primary end point of this phase II trial was progres-
sion free survival rate at 9 months (PFSR@9). A single-
stage study design was planned. The primary goal was
to demonstrate a PFSR@9 of at least 50%, similarly to
the efficacy reported with 5FU/LV and bevacizumab.
Treatment with capecitabine and bevacizumab would
however be seen as insufficiently effective if PFSR@9
would be not more than 35% (which corresponds to a
progression-free survival of 6 months). With 85% power
and one-sided type I error of 0.05 the required sample
size was 76 patients. With a drop out rate of 5%, 82 pa-
tients were to be included. Baseline patient characteris-
tics, response, and toxic effects were described using
summary statistics. The Kaplan-Meier-method was used
Stein et al. BMC Cancer 2013, 13:454 Page 3 of 7
http://www.biomedcentral.com/1471-2407/13/454to analyze the primary endpoint and censored event
times. 95%-confidence intervals (CI) were given for all
calculated estimates.Results
Patients’ characteristics
Between December 2006 and September 2008, a total of
82 patients were enrolled at 20 German study sites. 4 pa-
tients did not receive any study treatment and were with-
drawn prior to administration of study drug (due to
infection, progression or protocol deviation) and are thus
not included in the safety population. Baseline characteris-
tics are summarized in Table 1. 40 female and 42 male pa-
tients with median age of 70 years (range 49–86 years)
and ECOG PS score of 0/1/2 in 38/52/10% respectively
were analyzed. Site of primary tumor was colon in 56 and
rectum in 26 patients. Synchronous metastatic disease
was present in 58 (72%) patients. Prior resection of pri-
mary tumor was performed in 66 (80%) patients.Table 1 Patients’ characteristics
Characteristic n % Years













Resected primary tumor 66 80
Prior radiotherapy for rectal primary 12 15
Adjuvant chemotherapy 19 23
Metastases (1 missing)




liver metastases 65 80
Prognosis score acc. to Kohne et al. (8 missing)
low risk 64 86
high risk 10 14
Abbreviations: ECOG Eastern Cooperative Oncology Group performance status,
n number.Treatment received
A total of 607 cycles was administered, with a median
number of 6 (range 1–24) cycles per patient. Median
treatment duration was 4.1 months (range 0.1-17.5) (for
bevacizumab 3.7 months). Dose reductions were adopted in
15% of the documented cycles and were mainly related to
capecitabine. Bevacizumab dose was only reduced in less
than 1% of the cycles. Overall 44 patients (56%) had to be
dose reduced. Treatment was delayed in 18% of cycles. Rea-
son for discontinuation of study treatment were progressive
disease in 41 (53%), toxicity in 8 (10%), withdrawal of con-
sent in 5 (6%), death (other than tumor) 5, protocol violation
2, resection/radiotherapy/local ablation in 3 patients and un-
known in 18 patients. Second- and third-line treatments
were administered to 47 and 27 patients (57% and 33%), re-
spectively. Oxaliplatin and irinotecan were applied in 29 and
35 patients (35% and 43%), respectively, with only 17 pa-
tients (21%) receiving both drugs consecutively. Salvage
treatment with EGFR antibodies was performed in 17 pa-
tients (21%), mostly combined with irinotecan (10 patients).Efficacy
The efficacy results were determined in the group of pa-
tients receiving at least one treatment (n = 78). Results
are summarized in Table 2. Progression free survival rate
at 9 months was 0.35 [95% CI (0.24-0.46)]. Objective re-
sponse rate (ORR) was 38% with 5 complete (7%) and 23
partial responses (31%). Stable disease as best response
was achieved in 31 patients (43%), resulting in a disease
stabilisation rate of 81%. After a median follow up of
12.7 months, median PFS was 7.0 months [95% CI (5.0-
9.1)] (Figure 1) and median OS was 17.9 months [95%
CI (14.6-21.6)] (Figure 2). The 1-year overall survival
rate was 67% [95% CI (56–79)]. The median duration of
response, defined as PFS of the subgroup of 28 patients
achieving objective response, was 8.9 months [95% CITable 2 Efficacy according to RECIST 1.0
Efficacy in patients receiving treatment (n = 78)
n %
Response rate (evaluable n = 73) (5 missing)
Complete response 5 7
Partial response 23 31
Stable disease 31 43
Progressive disease or death 14 19
95% CI
PFS rate at 9 months 0.35 0.24-0.46
PFS 7.0 months 5.0-9.1
OS 17.9 months 14.6-21.6
Abbreviations: n number, PFS Progression free survival, OS Overall survival,
CI Confidence interval.
Figure 1 Kaplan–Meier survival curve demonstrating progression-free survival.
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jective response in this subgroup was 3.4 months.Toxicity
Treatment was generally well tolerated in an outpatient
setting. Adverse events are summarized in Table 3. The
most frequently observed adverse event were hand-foot
skin reaction (57% of patients) and infection (37%). 16
patients (21%) experienced grade 3 hand-foot skin reac-
tion. Hypertension occurred in 17 patients (22%) all
grades and grade 3 in 3 patients. Diarrhea (33%, grade
3/4 in 6%) and nausea (28%, grade 3/4 in 5%) were the
most frequently observed gastrointestinal toxicities.
Thromboembolic events occurred in 12 patients (15%)
all grades and grade 3 in 8 patients (10%). No grade 4
thromboembolic event occurred. Overall, the combination
of capecitabine and bevacizumab was generally wellFigure 2 Kaplan–Meier survival curve demonstrating overall survival.tolerated and the majority of adverse events were of
mild to moderate intensity.
There were only 6 patients (8%) who experienced grade 4
adverse events, namely hematological toxicity, diarrhea,
ileus, gastrointestinal perforation, blood infection and small
bowel infection in one patient each. The 60-day mortality
based on 78 evaluable patients was 3.8% (n = 3) and is
within the expected range for this patient population.Discussion
Randomized clinical studies in patients with metastatic
colorectal cancer have shown that bevacizumab improves
response rates, progression-free survival and overall sur-
vival when combined with standard fluoropyrimidine
based chemotherapy compared with chemotherapy alone
[5,10,12,16,18,19]. Thus, bevacizumab in combination
with chemotherapy (combination or single agent) has
Table 3 Toxicity according to National Cancer Institute




3/4(safety population n = 78)
pts (n) % pts (n) %
Leucopenia 2 2 0 0
Anemia 4 5 1 1
Thrombocytopenia 4 5 1 1
Infection 29 37 6 7
Fatigue/Asthenia 20 25 1 1
Diarrhea 26 33 5 6
Mucositis 14 18 1 1
Nausea 22 28 4 5
Vomiting 9 12 1 1
Anorexia 8 10 1 1
Hand-foot-syndrome 44 57 16 21
Gastrointestinal perforation 2 2 2 2
Hemorrhage 10 13 1 1
Hypertension 17 22 3 4
Thromboembolic events 12 15 8 10
Abbreviation: pts (n) number of patients.
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metastatic colorectal cancer.
Upfront stratification of patients according to patients’
and disease characteristics and the respective treatment
aims seem to be of importance for the overall outcome and
is reflected by current guidelines. Single agent or two drug
regimens with fluoropyrimidines are recommended for pa-
tients presenting with non-resectable and/or asymptomatic
disease, and/or co-morbidity, excluding from intensive first
line chemotherapy or later surgery [9]. Besides clinical
grouping according to the above-mentioned criteria, age
and frailty are used for upfront patient stratification, al-
though particularly frailty is not well defined. The
FOCUS 2 trial included patients based on these criteria,
who were randomized to fluoropyrimidines with or
without oxaliplatin (with reduced starting dose), show-
ing the feasibility and the beneficial impact of the com-
bination regimen [20]. The recently reported phase III
AVEX trial included patients of at least 70 years of age,
deemed no optimal candidates for upfront irinotecan or
oxaliplatin based chemotherapy, whereas the phase III
AGITG-MAX trial included patients independent of age
suitable for first line single agent [12,16]. Patients were
randomized to capecitabine with or without bevacizumab
(+/− mitomycin in AGITG-MAX). In both trials, the com-
bination of capecitabine and bevacizumab resulted in sig-
nificant and clinically meaningful improvement of PFS and
showed a favourable ORR and OS compared to single agentcapecitabine. Interestingly, all randomized trials with one of
the somewhat less intensive chemotherapy backbones (i.e.
IFL bolus regimen, 5FU/LV bolus regimens; capecitabine)
showed consistently an impressive improvement of PFS
(HR 0,54; 0,50 and 0,63 respectively) when bevacizumab
was added to that backbone [10,12,19].
The here reported AIO KRK 0105 trial included patients,
deemed to be unresectable independent of co-morbidity,
age, symptoms or appropriateness for intensive first line
chemotherapy. Median PFS seemed to be better in the
AVEX and AGITG-MAX trials (9.1 and 8.5 months) com-
pared to AIO KRK 0105 (7 months). Besides general limi-
tation of a single arm phase II trial, patient selection and
thus included patient population differed between the tri-
als. Although overall patient characteristics (e.g. median
age) were similar between the mentioned trials, some rele-
vant differences were noted. The relatively high rate of
symptomatic patients in the AIO KRK 0105 with 62% of
patients with at least ECOG 1, compared to 48% or 44% in
the AVEX and AGITG-MAX trials and the high rate of
synchronous metastases in 72% of patients indicate a pa-
tient population with adverse prognostic features and high
tumour load. Moreover, treatment duration, applied dose
of capecitabine and subsequent treatment might have im-
pacted on the different outcomes.
Median treatment duration of capecitabine and
bevacizumab in the AIO KRK 0105 was 4.1 months, com-
pared to 5.8 in AVEX and about 7 months in AGITG-
MAX. The lower dosage of capecitabine (2 g/m2) in the
AVEX trial and in about two thirds of the AGITG-MAX
trial patients’ and thus a better and sustained tolerability
might have been the reason for the longer treatment dur-
ation. However, besides the shorter treatment duration
the higher dosage of capecitabine with 2.5 g/m 2 in the
AIO KRK 0105 was well tolerated, particularly in regard
of only 6% grade 3/4 diarrhoea.
Interestingly, second line chemotherapy was applied
more often in the AIO KRK 0105 trial compared to the
AVEX trial (57 vs. 37%). Moreover, rates of subsequent
treatment with oxaliplatin (35 vs. 1.4%, AIO KRK 0105 vs.
AVEX) or irinotecan (43 vs. 6%) highly differed. In the
MAX trial only 17% in the capecitabine and bevacizumab
arm received irinotecan and oxaliplatin in subsequent
treatment lines.
Despite rarely used second line chemotherapy, the me-
dian PFS of 9.1 months resulted in a median OS of
20.7 months in the AVEX trial. It might thus be specu-
lated, whether first-line treatment of bevacizumab in
combination with capecitabine might preferably be used
in elderly patients with rather indolent disease and a low
chance of receiving subsequent treatment (assumed
AVEX population) and maybe not ideally as initial treat-
ment in patients with symptoms due to higher tumour
load and/or worse prognostic features (e.g. synchronous
Stein et al. BMC Cancer 2013, 13:454 Page 6 of 7
http://www.biomedcentral.com/1471-2407/13/454disease), who are eligible for irinotecan and oxaliplatin-
based chemotherapy (AIO KRK 0105 population).
However, first-line treatment of capecitabine and
bevacizumab was well tolerated. Most adverse events were
of mild to moderate intensity. The toxicity profile was as
expected for the agents used. The most frequently ob-
served adverse events were hand-foot syndrome, diarrhea,
nausea, mucositis, fatigue, hypertension and thrombosis.
Conclusion
Although the median PFS in the 78 patients who received
study treatment was lower than expected and thus the pri-
mary study end point not met, the efficacy results of the
trial are within the range of other capecitabine and
bevacizumab combinations. Upfront patient selection and
treatment stratification seem to be of utmost importance.
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